M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia

Neuron

Volumn 88, Issue 4, 2015, Pages 762-773

  Shen, Weixing ^a   Plotkin, Joshua L ^a   Francardo, Veronica ^b   Ko, Wai Kin D ^c,d,e   Xie, Zhong ^a   Li, Qin ^e   Fieblinger, Tim ^b   Wess, Jürgen ^f   Neubig, Richard R ^g   Lindsley, Craig W ^h   Conn, P Jeffrey ^h   Greengard, Paul ⁱ   Bezard, Erwan ^c,d,e   Cenci, M Angela ^b   Surmeier, D James ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^e Williams House   (United Kingdom)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g MICHIGAN STATE UNIVERSITY   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CALCIUM ION; MUSCARINIC AGENT; MUSCARINIC M4 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RGS4 PROTEIN; UNCLASSIFIED DRUG; VU 0152100; VU 0467154; VU 0476406; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; LEVODOPA; RGS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; EX VIVO STUDY; LEVODOPA-INDUCED DYSKINESIA; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MOUSE; NERVE CELL PLASTICITY; NERVE PROJECTION; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ALLOSTERISM; ANIMAL; BRAIN CORTEX; DISEASE MODEL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; METABOLISM; NEOSTRIATUM; NERVE CELL; PARKINSONIAN DISORDERS; RHESUS MONKEY; TRANSGENIC MOUSE;

ALLOSTERIC REGULATION; ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; GLUTAMIC ACID; LEVODOPA; LONG-TERM POTENTIATION; LONG-TERM SYNAPTIC DEPRESSION; MACACA MULATTA; MICE; MICE, TRANSGENIC; NEOSTRIATUM; NEURONAL PLASTICITY; NEURONS; PARKINSONIAN DISORDERS; RECEPTOR, MUSCARINIC M4; RGS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84954519551     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2015.10.039     Document Type: Article

References (63)

1. Augustin S.M., Beeler J.A., McGehee D.S., Zhuang X. Cyclic AMP and afferent activity govern bidirectional synaptic plasticity in striatopallidal neurons. J. Neurosci. 2014, 34:6692-6699.
2. Belujon P., Lodge D.J., Grace A.A. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. Mov. Disord. 2010, 25:1568-1576.
3. Bernard V., Normand E., Bloch B. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J. Neurosci. 1992, 12:3591-3600.
4. Bézard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 2003, 9:762-767.
5. Blazer L.L., Storaska A.J., Jutkiewicz E.M., Turner E.M., Calcagno M., Wade S.M., Wang Q., Huang X.-P., Traynor J.R., Husbands S.M., et al. Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors. ACS Chem. Neurosci. 2015, 6:911-919.
6. 4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther. 2008, 327:941-953.
7. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007, 30:211-219.
8. Cenci M.A. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci. 2007, 30:236-243.
9. Cenci M.A., Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. 2007, Chapter 9:25.
10. Cerovic M., Bagetta V., Pendolino V., Ghiglieri V., Fasano S., Morella I., Hardingham N., Heuer A., Papale A., Marchisella F., et al. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia. Biol. Psychiatry 2015, 77:106-115.
11. Conn, P.J., Lindsley, C.W., Wood, M.R., Hopkins, C.R., Salovich, J.M., and Melancon, B.J. (2014). Substituted pyrazolo[3',4',4,5]thieno[2,3-c]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic receptor M4. Patent WO0364409.
12. Feyder M., Bonito-Oliva A., Fisone G. L-DOPA-Induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front. Behav. Neurosci. 2011, 5:71.
13. Fieblinger T., Graves S.M., Sebel L.E., Alcacer C., Plotkin J.L., Gertler T.S., Chan C.S., Heiman M., Greengard P., Cenci M.A., Surmeier D.J. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat. Commun. 2014, 5:5316.
14. Fino E., Paille V., Cui Y., Morera-Herreras T., Deniau J.-M., Venance L. Distinct coincidence detectors govern the corticostriatal spike timing-dependent plasticity. J. Physiol. 2010, 588:3045-3062.
15. Fox S.H., Johnston T.H., Li Q., Brotchie J., Bezard E. A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Mov. Disord. 2012, 27:1373-1378.
16. Francardo V., Recchia A., Popovic N., Andersson D., Nissbrandt H., Cenci M.A. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol. Dis. 2011, 42:327-340.
17. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 2011, 34:441-466.
18. 4 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. USA 1999, 96:10483-10488.
19. Hersch S.M., Gutekunst C.A., Rees H.D., Heilman C.J., Levey A.I. Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J. Neurosci. 1994, 14:3351-3363.
20. 2+ influx by D2 dopamine and A2A adenosine receptors. Nat. Neurosci. 2010, 13:958-966.
21. Higley M.J., Soler-Llavina G.J., Sabatini B.L. Cholinergic modulation of multivesicular release regulates striatal synaptic potency and integration. Nat. Neurosci. 2009, 12:1121-1128.
22. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 2008, 9:665-677.
23. 4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J. Neurosci. 2010, 30:2396-2405.
24. Kaneko S., Hikida T., Watanabe D., Ichinose H., Nagatsu T., Kreitman R.J., Pastan I., Nakanishi S. Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science 2000, 289:633-637.
25. Ko W.K.D., Pioli E., Li Q., McGuire S., Dufour A., Sherer T.B., Bezard E., Facheris M.F. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Mov. Disord. 2014, 29:772-779.
26. Krapivinsky G., Krapivinsky L., Manasian Y., Ivanov A., Tyzio R., Pellegrino C., Ben-Ari Y., Clapham D.E., Medina I. The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron 2003, 40:775-784.
27. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445:643-647.
28. Lee H.K., Barbarosie M., Kameyama K., Bear M.F., Huganir R.L. Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 2000, 405:955-959.
29. Lerner T.N., Kreitzer A.C. Neuromodulatory control of striatal plasticity and behavior. Curr. Opin. Neurobiol. 2011, 21:322-327.
30. Lerner T.N., Kreitzer A.C. RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits. Neuron 2012, 73:347-359.
31. 2A antagonists. J. Neurosci. 2010, 30:2160-2164.
32. Lovinger D.M. Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology 2010, 58:951-961.
33. Maia T.V., Frank M.J. From reinforcement learning models to psychiatric and neurological disorders. Nat. Neurosci. 2011, 14:154-162.
34. Metman L.V., Del Dotto P., LePoole K., Konitsiotis S., Fang J., Chase T.N. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol. 1999, 56:1383-1386.
35. 2+ signaling in spines. J. Neurosci. 2014, 34:869-879.
36. Nazzaro C., Greco B., Cerovic M., Baxter P., Rubino T., Trusel M., Parolaro D., Tkatch T., Benfenati F., Pedarzani P., Tonini R. SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance. Nat. Neurosci. 2012, 15:284-293.
37. Otmakhova N.A., Lisman J.E. D1/D5 dopamine receptors inhibit depotentiation at CA1 synapses via cAMP-dependent mechanism. J. Neurosci. 1998, 18:1270-1279.
38. Pancani T., Bolarinwa C., Smith Y., Lindsley C.W., Conn P.J., Xiang Z. M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses. ACS Chem. Neurosci. 2014, 5:318-324.
39. Pascoli V., Turiault M., Lüscher C. Reversal of cocaine-evoked synaptic potentiation resets drug-induced adaptive behaviour. Nature 2012, 481:71-75.
40. Pawlak V., Kerr J.N.D. Dopamine receptor activation is required for corticostriatal spike-timing-dependent plasticity. J. Neurosci. 2008, 28:2435-2446.
41. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 2003, 6:501-506.
42. Picconi B., Passino E., Sgobio C., Bonsi P., Barone I., Ghiglieri V., Pisani A., Bernardi G., Ammassari-Teule M., Calabresi P. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol. Dis. 2006, 22:143-152.
43. Plotkin J.L., Day M., Peterson J.D., Xie Z., Kress G.J., Rafalovich I., Kondapalli J., Gertler T.S., Flajolet M., Greengard P., et al. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron 2014, 83:178-188.
44. Rogan S.C., Roth B.L. Remote control of neuronal signaling. Pharmacol. Rev. 2011, 63:291-315.
45. 4 receptor. Neurochem. Res. 2009, 34:1363-1371.
46. Santini E., Alcacer C., Cacciatore S., Heiman M., Hervé D., Greengard P., Girault J.-A., Valjent E., Fisone G. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J. Neurochem. 2009, 108:621-633.
47. Saugstad J.A., Marino M.J., Folk J.A., Hepler J.R., Conn P.J. RGS4 inhibits signaling by group I metabotropic glutamate receptors. J. Neurosci. 1998, 18:905-913.
48. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
49. Shen W., Tian X., Day M., Ulrich S., Tkatch T., Nathanson N.M., Surmeier D.J. Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. Nat. Neurosci. 2007, 10:1458-1466.
50. Shen W., Flajolet M., Greengard P., Surmeier D.J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
51. 2+ threshold for induction of spike-timing-dependent depression in the mouse striatum. J. Neurosci. 2011, 31:13015-13022.
52. 4 mAChR modulates hippocampal synaptic transmission. Nat. Chem. Biol. 2008, 4:42-50.
53. Sweatt J.D. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr. Opin. Neurobiol. 2004, 14:311-317.
54. Thiele S.L., Chen B., Lo C., Gertler T.S., Warre R., Surmeier J.D., Brotchie J.M., Nash J.E. Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models. Neurobiol. Dis. 2014, 71:334-344.
55. Threlfell S., Lalic T., Platt N.J., Jennings K.A., Deisseroth K., Cragg S.J. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 2012, 75:58-64.
56. 2A receptor interaction in the striatum: implications for Parkinson's disease. J. Neurosci. 2011, 31:1850-1862.
57. Wang Z., Kai L., Day M., Ronesi J., Yin H.H., Ding J., Tkatch T., Lovinger D.M., Surmeier D.J. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006, 50:443-452.
58. Wickens J.R., Reynolds J.N.J., Hyland B.I. Neural mechanisms of reward-related motor learning. Curr. Opin. Neurobiol. 2003, 13:685-690.
59. Won L., Ding Y., Singh P., Kang U.J. Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice. J. Neurosci. 2014, 34:3090-3094.
60. Wu Y.-W., Kim J.-I., Tawfik V.L., Lalchandani R.R., Scherrer G., Ding J.B. Input- and cell-type-specific endocannabinoid-dependent LTD in the striatum. Cell Rep. 2015, 10:75-87.
61. Yagishita S., Hayashi-Takagi A., Ellis-Davies G.C.R., Urakubo H., Ishii S., Kasai H. A critical time window for dopamine actions on the structural plasticity of dendritic spines. Science 2014, 345:1616-1620.
62. Yin H.H., Knowlton B.J. The role of the basal ganglia in habit formation. Nat. Rev. Neurosci. 2006, 7:464-476.
63. Zhou F.-M., Wilson C., Dani J.A. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 2003, 9:23-36.